Showing results (531-540 of 555) with videos related to

Sort By:
Pageof 56
Schizophrenia Research|May 26, 2020
Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation studyTsutomu Takahashi, Sakiko Tsugawa, Shinichiro Nakajima, et al.
Science Translational Medicine|December 10, 2025
A bioinspired mineralized collagen scaffold promotes enthesis healing and activates Gli1 expression in preclinical modelsTao Zhang, Tingyun Lei, Jie Han, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|July 15, 2025
Transforming Growth Factor-β Serum Levels Associated with Social Function in Subjects at Ultra-high Risk for Psychosis: A Multicenter StudyYuji Yamada, Naoko Kishimoto, Hiromi Tagata, et al.
Biological Psychiatry|September 14, 2010
Genome-wide association study of schizophrenia in a Japanese populationMasashi Ikeda, Branko Aleksic, Yoko Kinoshita, et al.
Neuroimage. Clinical|December 5, 2017
The effect of duration of illness and antipsychotics on subcortical volumes in schizophrenia: Analysis of 778 subjectsNaoki Hashimoto, Yoichi M Ito, Naohiro Okada, et al.
Frontiers in Pharmacology|October 31, 2022
An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's diseaseMosaburo Kainuma, Shinji Ouma, Shinobu Kawakatsu, et al.
Schizophrenia Bulletin|October 22, 2014
Identification of Rare, Single-Nucleotide Mutations in NDE1 and Their Contributions to Schizophrenia SusceptibilityHiroki Kimura, Daisuke Tsuboi, Chenyao Wang, et al.
Zoological Science|October 16, 2013
The diversity of shell matrix proteins: genome-wide investigation of the pearl oyster, Pinctada fucataHiroshi Miyamoto, Hirotoshi Endo, Naoki Hashimoto, et al.
Frontiers in Pharmacology|June 28, 2023
Metabolic changes in the plasma of mild Alzheimer's disease patients treated with HachimijioganMosaburo Kainuma, Shinobu Kawakatsu, Jun-Dal Kim, et al.
Pageof 56